Adult Dosing
Prophylaxis rejection renal transplantation
- Usual dose 20 mg IV x 2
- First dose: 20 mg IV given within 2 hrs prior to transplant
- Second dose: 20 mg IV given 4 days after transplant
Pediatric Dosing
Prophylaxis rejection renal transplantation
<35 kg
- Usual dose 10 mg IV x 2
- First dose: 10 mg IV given within 2 hrs prior to transplant
- Second dose: 10 mg IV given 4 days after transplant
>35 kg
- Usual dose 20 mg IV x 2
- First dose: 20 mg IV given within 2 hrs prior to transplant
- Second dose: 20 mg IV given 4 days after transplant
- Basiliximab should be administered under qualified medical supervision. Physicians should inform patient of the potential benefits of therapy and the risks associated with therapy
- Patients while on immunosuppressive therapy are at increased risk for developing lymphoproliferative disorders and opportunistic infections and should be monitored accordingly
- Severe acute hypersensitivity reactions including anaphylaxis, hypotension, tachycardia, cardiac failure, dyspnea, wheezing, bronchospasm, pulmonary edema, respiratory failure, urticaria, rash, pruritus, and sneezing have been observed both on initial exposure to therapy and following re-exposure after several months
- Patients are at risk of developing severe hypersensitivity reactions on re-administration of therapy especially in whom concomitant immunosuppression was discontinued prematurely following the initial administration of therapy
- Discontinue therapy if a severe hypersensitivity reaction occurs and medications for the treatment of severe hypersensitivity reactions including anaphylaxis should be available for immediate use
- Long-term effect on the ability of the immune system to respond to antigens first encountered during basiliximab-induced immunosuppression is not known
Cautions: Use cautiously in
- Prior use
- Elderly patients
Pregnancy Category:B
Breastfeeding: It is unknown whether basiliximab is excreted in human milk. However many drugs including human antibodies are excreted in human milk. Manufacturer advises because of the potential for adverse reactions, a decision should be made to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
